TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06715839
Drug: [68Ga]Ga-NOTA-WWH347
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.
Study: NCT06715839
Drug: [18F]F-RESCA-WWH347
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.
Study: NCT06715839
Drug: [68Ga]Ga-NOTA-RND20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.
Study: NCT06715839
Drug: [18F]F-RESCA-RND20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
Study: NCT06714825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT06457477
Drug: NAs
Normalized name: DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT05833035
Drug: BI 1291583 mixed with [C-14] BI 1291583
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 mixed with \[C-14\] BI 1291583
Study: NCT05745610
Drug: Shen Hai Long Capsule
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times/day (9 capsules/day) for 12 weeks
Study: NCT05219253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
Study: NCT06243614
Drug: Buagafuran capsules, 15mg/ capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Study: NCT06243614
Drug: Buspirone tablets, 5mg/ tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study: NCT06243614
Drug: Buagafuran capsules mimic, 0mg/ capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Study: NCT06243614
Drug: Buspirone tablets mimic, 0mg/ tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study: NCT03712826
Drug: Anti-TNF Drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crohn patient with antiTNF treatment
Study: NCT05759208
Drug: OK-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT05759208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00005010
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04726345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to be taken orally once a day until stent removal.
Study: NCT06332508
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy.
Study: NCT01634230
Drug: OCR-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dose: 10 g infused over 24 hours
Study: NCT05160506
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone is a steroid (corticosteroid) medication.
Study: NCT05160506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50ml of 0.9% NACL will serve as the placebo
Study: NCT04951765
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
Study: NCT04951765
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
Study: NCT04951765
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
Study: NCT04951765
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
Study: NCT04951765
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
Study: NCT04951765
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
Study: NCT04847440
Drug: AB-729
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
Study: NCT06007417
Drug: GenSci004
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
Study: NCT05842525
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT05751148
Drug: Hyperbaric bupivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
Study: NCT05267535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT03646058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills, sublingual, specifically made to mimick buprenorphine pills
Study: NCT02526303
Drug: Nadroparin Calcium and Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
Study: NCT05071612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT04922853
Drug: Capox chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
Study: NCT05663463
Drug: Fluzone High-Dose - 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
Study: NCT05663463
Drug: Fluzone High-Dose - 1 dose of HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
Study: NCT06175780
Drug: KY-0118
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
Study: NCT06175780
Drug: KY-0118
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
Study: NCT06175780
Drug: KY-0118
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
Study: NCT05042401
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo low dose
Study: NCT05042401
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo high dose
Study: NCT05411107
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06498115
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
Study: NCT04873440
Drug: Chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
Study: NCT04738175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT06281977
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programed as dexmedetomidine on infusion pump.
Study: NCT04684381
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic study
Study: NCT05844202
Drug: Alveavax-v1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
Study: NCT05844202
Drug: Janssen Ad26.COV2.S
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine by Janssen / Johnson \& Johnson
Study: NCT05180214
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: analgesia
Study: NCT05210504
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal (0.9%) Saline
Study: NCT06334874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch placebo capsule
Study: NCT05528406
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg bid po
Study: NCT06046066
Drug: NM6603
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
Study: NCT04892706
Drug: IDP-126 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel applied to face once daily in the evening.
Study: NCT04892706
Drug: IDP-126 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel applied to face once daily in the evening.
Study: NCT04892706
Drug: Epiduo® Forte Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel applied to face once daily in the evening.
Study: NCT05494268
Drug: Carbohydrate
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Carbohydrate Loading Drink
Study: NCT06423144
Drug: PD-1/PD-L1 inhibits and anti-angiogenic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents were administrated based on the instructions recommended
Study: NCT05698147
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Study: NCT05756920
Drug: ABL301
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
Study: NCT05756920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
Study: NCT05673824
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher.
Study: NCT05077839
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
Study: NCT06069180
Drug: Flu/Cy/ATG or Cy/ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
Study: NCT05973370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT03903549
Drug: [18F]P17-059
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
Study: NCT06401499
Drug: etoricoxib 60mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
Study: NCT06167226
Drug: Personalized Ayurveda treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
Study: NCT05282875
Drug: management of immunosuppressive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents
Study: NCT04636567
Drug: Nerindocianine for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: routine minimally invasive abdominopelvic surgery.
Study: NCT06151470
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06151470
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT04891913
Drug: SY-007/ Placebo 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study: NCT04891913
Drug: SY-007/ Placebo 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study: NCT04891913
Drug: SY-007/ Placebo 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study: NCT04676893
Drug: D418 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT04676893
Drug: CKD-388 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT04915508
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive hormonal therapy
Study: NCT04829565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
Study: NCT05340673
Drug: Agent Affecting Integumentary System
Normalized name: ANTIACNE AGENTS,SYSTEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply Miaderm
Study: NCT06011317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally once daily
Study: NCT04834908
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
Study: NCT05735756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day for 12 weeks
Study: NCT04518254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
Study: NCT06511947
Drug: 5 Methoxy N,N Dimethyltryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH001 administered via inhalation
Study: NCT05128071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to placebo twice daily
Study: NCT00240812
Drug: ibuprofen; pseudoephedrine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05056558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
Study: NCT05023525
Drug: HSK31858, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose in single ascending dose: 5 mg
Study: NCT05023525
Drug: Placebo, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03787628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
Study: NCT05543122
Drug: either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
Study: NCT05985707
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
Study: NCT05259007
Drug: Amoxicillin-Clarithromycin-Lansoprazole
Normalized name: AMOXICILLIN/CLARITHROMYCIN/LANSOPRAZOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication treatment
Study: NCT06237595
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for fibromyalgia patients
Study: NCT06133556
Drug: MCBC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
Study: NCT06133556
Drug: Bu/Cy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group, the standard conditioning regimen Busulfan/Cyclophosphamide
Study: NCT05120739
Drug: 2% CHX cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: skin preparation in 2% CHX cloths
Study: NCT05144828
Drug: Patient-controlled analgesia (PCA)
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
Study: NCT05011149
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent.
Study: NCT06387069
Drug: HMPL-306 Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.